U.S., June 4 -- ClinicalTrials.gov registry received information related to the study (NCT07622524) titled 'A Phase I Study of CS5007 in Participants With Advanced Solid Tumors' on May 28.
Brief Summary: This is a first-in-human (FIH), open-label, and multi-center Phase I study designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of CS5007 as monotherapy in participants with advanced solid tumors. The study is comprised of a Phase Ia dose escalation and Phase Ib dose expansion.
Study Start Date: June, 2026
Study Type: INTERVENTIONAL
Condition:
Advanced Solid Tumors
Intervention:
DRUG: CS5007
CS5007 will be administered via intravenous (IV) infusion on Day 1 of repeated 21-day cycles (Q...